Treatment of relapsing remitting MS with BTK inhibition appears to be well tolerated and effective on MRI, the European Association of Neurology (EAN) 2020 Virtual Congress was told. Professor Daniel Reich, from the US National Institute of Neurological Disorders and Stroke, presented the results of a phase 2b study in about 200 patients randomised to ...
EAN 2020: Bruton kinase inhibitors show promise in MS
By Mardi Chapman
4 Jun 2020